| P50 | author | Emin Kaya | Q58649156 |
| P2093 | author name string | Oktay Bilgir | |
| | Fahri Şahin | |
| | Filiz Vural | |
| | Füsun Özdemirkıran | |
| | Güray Saydam | |
| | Osman İlhan | |
| | Mehmet Yılmaz | |
| | İbrahim C Haznedaroğlu | |
| | Ali Ünal | |
| | Nur Soyer | |
| | Melda Cömert | |
| | Demet Çekdemir | |
| | Gülsüm Çağlıyan | |
| P2860 | cites work | Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia | Q80996436 |
| | Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution | Q81528363 |
| | Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors | Q82523723 |
| | Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications | Q84594893 |
| | The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 |
| | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management | Q26851894 |
| | Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis | Q27853043 |
| | Efficacy and safety of low-dose aspirin in polycythemia vera | Q28166691 |
| | Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera | Q28210331 |
| | Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia | Q28213633 |
| | Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | Q31153850 |
| | DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 |
| | Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France) | Q33726712 |
| | Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study | Q34037065 |
| | Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies | Q34158356 |
| | Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study | Q36157668 |
| | Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Q36946576 |
| | Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 |
| | Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation | Q37272559 |
| | Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture | Q38037237 |
| | Myeloproliferative neoplasms and thrombosis. | Q38119076 |
| | Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options | Q38255717 |
| | Molecular diagnostics of myeloproliferative neoplasms. | Q38464571 |
| | Vascular and neoplastic risk in a large cohort of patients with polycythemia vera | Q40445951 |
| | Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study | Q41600141 |
| | Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. | Q43898090 |
| | Unique features of primary myelofibrosis in Chinese | Q45309511 |
| | Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia | Q46847956 |
| | Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. | Q50528661 |
| | Improving survival trends in primary myelofibrosis: an international study. | Q53126695 |
| | Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study | Q56984881 |
| | Thrombosis in primary myelofibrosis: incidence and risk factors | Q61050096 |
| | Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia | Q71777805 |
| | Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status | Q79365558 |
| | Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients | Q79434773 |
| | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 |
| | Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation | Q80575698 |
| P433 | issue | 1 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P304 | page(s) | 27-33 | |
| P577 | publication date | 2016-04-18 | |
| P1433 | published in | Turkish journal of hematology : official journal of Turkish Society of Haematology | Q26842860 |
| P1476 | title | Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms | |
| P478 | volume | 34 | |